Trials / Completed
CompletedNCT00002663
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
An Evaluation of the Toxicity and Therapeutic Effects of Epstein-Barr Virus-Immune T-Lymphocytes Derived From a Normal HLA-Compatible or Haplotype-Matched Donor in the Treatment of EBV-Associated Lymphoproliferative Diseases or Malignancies and Patients With Detectable Circulating Levels of EBV DNA Who Are at High Risk for EBV-Associated Lymphoproliferative Diseases
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 58 (actual)
- Sponsor
- Atara Biotherapeutics · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this phase I/II trial is to study the side effects and best dose of biological therapy to treat patients at high-risk or with Epstein-Barr virus-associated lymphoma or lymphoproliferative disease.
Conditions
- EBV-induced Lymphomas
- EBV-associated Malignancies
- Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs) | EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders. |
Timeline
- Start date
- 1995-03-01
- Primary completion
- 2019-07-01
- Completion
- 2019-07-01
- First posted
- 2003-01-27
- Last updated
- 2023-02-13
- Results posted
- 2023-02-13
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00002663. Inclusion in this directory is not an endorsement.